Nelfinavir mesylate AG1343
Nelfinavir mesylate AG1343 Brand names, Nelfinavir mesylate AG1343 Analogs
Nelfinavir mesylate AG1343 Brand Names Mixture
- No information avaliable
Nelfinavir mesylate AG1343 Chemical_Formula
C32H45N3O4S
Nelfinavir mesylate AG1343 RX_link
http://www.rxlist.com/cgi/generic2/nelfin.htm
Nelfinavir mesylate AG1343 fda sheet
Nelfinavir mesylate AG1343 msds (material safety sheet)
Nelfinavir mesylate AG1343 Synthesis Reference
No information avaliable
Nelfinavir mesylate AG1343 Molecular Weight
567.784 g/mol
Nelfinavir mesylate AG1343 Melting Point
349.84 oC
Nelfinavir mesylate AG1343 H2O Solubility
Slightly soluble
Nelfinavir mesylate AG1343 State
Solid
Nelfinavir mesylate AG1343 LogP
5.247
Nelfinavir mesylate AG1343 Dosage Forms
Tablet (oral - 250 mg, 625 mg); Powder (oral)
Nelfinavir mesylate AG1343 Indication
Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
Nelfinavir mesylate AG1343 Pharmacology
Nelfinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
Nelfinavir mesylate AG1343 Absorption
Well absorbed following oral administration.
Nelfinavir mesylate AG1343 side effects and Toxicity
Oral LD50 is over 5g/kg in rats. Side effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.
Nelfinavir mesylate AG1343 Patient Information
PATIENT INFORMATION
Patients should be informed that VIRACEPT is not a cure for HIV infection and that they may
continue to acquire illnesses associated with advanced HIV infection, including opportunistic
infections.
Patients should be told that the long-term effects of VIRACEPT are unknown at this time. They
should be told that there is currently no data demonstrating that VIRACEPT therapy can reduce
the risk of transmitting HIV to others through sexual contact or blood contamination.
Patients should be advised to take VIRACEPT every day as prescribed. Patients should not alter
the dose or discontinue therapy without consulting with their doctor. If a dose is missed, patients
should take the dose as soon as possible and then return to their normal schedule. However, if a dose
is skipped, the patient should not double the next dose.
The most frequent adverse event associated with VIRACEPT is diarrhea, which can usually be controlled
with non-prescription drugs, such as loperamide, which slow gastrointestinal motility.
VIRACEPT may interact with some drugs, therefore, patients should be advised to report to their doctor
the use of any other prescription or non-prescription medication.
Patients receiving oral contraceptives should be instructed that alternate or additional contraceptive
measures should be used during therapy with VIRACEPT.
Patients should be informed that VIRACEPT is not a cure for HIV infection and that they may
continue to acquire illnesses associated with advanced HIV infection, including opportunistic
infections.
Patients should be told that the long-term effects of VIRACEPT are unknown at this time. They
should be told that there is currently no data demonstrating that VIRACEPT therapy can reduce
the risk of transmitting HIV to others through sexual contact or blood contamination.
Patients should be advised to take VIRACEPT every day as prescribed. Patients should not alter
the dose or discontinue therapy without consulting with their doctor. If a dose is missed, patients
should take the dose as soon as possible and then return to their normal schedule. However, if a dose
is skipped, the patient should not double the next dose.
The most frequent adverse event associated with VIRACEPT is diarrhea, which can usually be controlled
with non-prescription drugs, such as loperamide, which slow gastrointestinal motility.
VIRACEPT may interact with some drugs, therefore, patients should be advised to report to their doctor
the use of any other prescription or non-prescription medication.
Patients receiving oral contraceptives should be instructed that alternate or additional contraceptive
measures should be used during therapy with VIRACEPT.
Nelfinavir mesylate AG1343 Organisms Affected
Human immunodeficiency virus
